Top gappers on : SLS, GP and PAVS
Market events
SELLAS (SLS) reports longer survival in its Phase 3 REGAL trial
SELLAS reported median survival of 24.0 versus 14.7 months in its Phase 3 REGAL trial. See who was studied, the FDA filing target and funding context.
Rank 1SLSSELLAS Life Sciences Group, Inc.
- Opening gap
- +222.69%
- Day
- +156.36%
- HOD (ET)
- 34.1908:33 ET
- Est. turnover
- $2.6B
- Gap-ups (≥1M shares)
- 674
On Nov. 17, 2026, SELLAS Life Sciences (SLS) reported that its randomized Phase 3 REGAL trial met its primary endpoint of overall survival. The study evaluated galinpepimut-S (GPS), an investigational cancer immunotherapy, as maintenance treatment for a specific group of patients with acute myeloid leukemia (AML). Nov. 17 Form 8-K and Exhibit 99.1